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Abstract
25-Hydroxyvitamin D (25(OH)D) half-life is a potential biomarker for investigating vitamin D metabolism and requirements. We performed
a pilot study to assess the approach and practical feasibility of measuring 25(OH)D half-life after an oral dose. A total of twelve healthy
Gambian men aged 18–23 years were divided into two groups to investigate the rate and timing of (1) absorption and (2) plasma disap-
pearance after an 80nmol oral dose of 25(OH)D2. Fasting blood samples were collected at baseline and, in the ﬁrst group, every 2h post-
dose for 12h, at 24h, 48h and on day 15. In the second group, fasting blood samples were collected on days 3, 4, 5, 6, 9, 12, 15, 18 and 21.
Urine was collected for 2h after the ﬁrst morning void at baseline and on day 15. 25(OH)D2 plasma concentration was measured by ultra-
performance liquid chromatography-tandem MS/MS and corrected for baseline. Biomarkers of vitamin D, Ca and P metabolism were
measured at baseline and on day 15. The peak plasma concentration of 25(OH)D2 was 9·6 (SD 0·9)nmol/l at 4·4 (SD 1·8)h. The terminal
slope of 25(OH)D2 disappearance was identiﬁed to commence from day 6. The terminal half-life of plasma 25(OH)D2 was 13·4 (SD 2·7)d.
There were no signiﬁcant differences in plasma 25(OH)D3, total 1,25(OH)2D, parathyroid hormone, P, Ca and ionised Ca and urinary Ca
and P between baseline and day 15 and between the two groups. The present study provides data on the plasma response to oral
25(OH)D2 that will underpin and contribute to the further development of studies to investigate 25(OH)D half-life.
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Vitamin D is required for skeletal health and Ca homeostasis.
Increasing evidence suggests a role for vitamin D in other
aspects of health and disease prevention
(1,2). Biomarkers
link health or disease outcomes to nutrient intake or supply
and provide a means to assess nutrient status at the individual
or population level
(1–3). The most frequently used biomarker
of vitamin D status is the serum or plasma concentration of
25-hydroxyvitamin D (25(OH)D). It is not under tight homeo-
static control and reﬂects vitamin D supply from cutaneous
synthesis and diet and usage, metabolism, excretion and
sequestration into body tissues
(3,4). There is considerable
debate over the level of 25(OH)D that represents optimal
vitamin D status. New tools and biomarkers are needed to
link vitamin D supply to tissue requirements and vitamin D
metabolism
(5,6). We have proposed the plasma half-life of
25(OH)D as a dynamic marker of vitamin D usage that may
be used to assess physiological requirements and to investi-
gate physiological, environmental and genetic inﬂuences on
vitamin D metabolism
(3). The aim is to develop a tracer
method for ﬁeld use in all population groups.
Previous studies have measured 25(OH)D absorption or
half-life in human subjects and animals using unlabelled
or radiolabelled compounds, but they have limitations. The
major disadvantage of unlabelled vitamin D metabolites is
that the plasma response cannot be distinguished from
endogenous vitamin D metabolites or vitamin D obtained
from the diet or cutaneous synthesis during the course of
the experiment. As a result, large doses are required that
may disturb habitual vitamin D, Ca and P metabolism.
The use of radiolabelled compounds is restricted to healthy
adults or speciﬁc groups of patients and is not suitable for
use in vulnerable groups.
Half-life is calculated from the terminal slope of the plasma
disappearance curve. After an intravenous or oral bolus dose,
there is typically a rapid and transient increase in plasma
concentration, followed by a relatively rapid decrease and
ﬁnally a gradual decline when equilibrium between body
pools is assumed. The terminal slope is determined by metab-
olism to downstream metabolites (including 1,25(OH)2D and
24,25(OH)2D) and catabolic pathways. The relatively long
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nhalf-life for 25(OH)D3 (10–40d)
(7–12) is in part determined
by the molar excess of vitamin D-binding protein (DBP) and
strong binding afﬁnity to DBP that protects 25(OH)D from
degradation and provides a circulating store of vitamin D.
Vitamin D metabolites with lower binding afﬁnities for
DBP have shorter half-lives
(13,14). A number of experimental
factors may affect the usefulness of methods to determine
half-life, including speciﬁcity of measurement, size of the
tracer dose, rapid mixing with endogenous pool and correctly
deﬁned terminal slope. In some studies, the 25(OH)D3 half-
life may have been calculated on the basis of data that
included time points that represented not only the terminal
slope but also the distribution phase
(12), and therefore a
faster half-life might have been predicted. In studies where
total plasma radioactivity was measured, all vitamin D metab-
olites were quantiﬁed and the presence of shorter- or longer-
lived metabolites may have affected the half-life
(11,15). In other
studies, tracer molecules were used with labelled atoms
in metabolically active positions that can affect 25(OH)D
and/or 1,25(OH)2D metabolism in vitro and in vivo
(16,17).
Alternatives to radiolabelled tracers are to use either stable
isotope or other suitable tracers with similar metabolism,
together with modern mass spectrometric methods. Here,
we report the use of 25(OH)D2 as a tracer, together with a sen-
sitive liquid chromatography (LC)-tandem MS method
(18),i na
pilot study to investigate vitamin D metabolism. We aimed to
characterise the absorption, distribution and terminal slope of
the plasma response to an oral dose of 25(OH)D2, a readily
available and cost-effective tracer. In addition, the effect of
the dose on vitamin D, Ca and P metabolism was evaluated.
The study was performed at MRC Keneba, a ﬁeld station in
rural Gambia at latitude 138N, where there is no or only lim-
ited seasonality in vitamin D status due to the year-round
UVB exposure from the sun
(19), and thus subjects are expected
to be in a steady state for vitamin D status for the duration of
the study. Furthermore, the dietary intake of vitamin D2 was
expected to be absent or very low in this population.
We used 25(OH)D2 rather than the parent compound,
vitamin D2, in order to minimise inter-individual differences
in absorption, tissue distribution and hydroxylation.
Methods
Subjects
The subjects were twelve healthy males, aged between 18
and 23 years (mean 19·8 years) and with a weight of 56·5
(SD 6·5)kg and BMI of 19·1 (SD 1·7)kg/m
2. The study was
conducted according to the guidelines laid down in the
Declaration of Helsinki and all procedures involving the
subjects were approved by the joint Gambian Government-
Medical Research Council’s ethics committee. Trained
ﬁeldworkers explained the study to the subjects in their native
language and informed written consent was obtained. Exclu-
sion criteria were recent illness (within last week), a broken
bone within the last 3 years, known bone, kidney or liver
disease, taking any prescription medicines or a Hb less than
100g/l. Fieldwork was performed during March and April 2009.
Dose preparation
25(OH)D2 (product number: 17937; purity $ 98%; Sigma-
Aldrich, Poole, UK) was weighed and dissolved in olive oil.
The solution was protected from light and mixed on a rotary
mixer at room temperature. Aliquots were frozen at 2208C
and were used within 2 weeks of preparation. Each dose con-
sisted of 80nmol (33mg) 25(OH)D2 in 810ml olive oil.
Study protocols
The volunteers were divided into two groups, the ‘absorption’
group (n 6) and the ‘half-life’ group (n 6), with different
sample timings but otherwise identical protocols. The size of
the dose and sampling protocols were chosen based on data
from the few previous estimates of absorption, kinetics and
turnover that used unlabelled and radiolabelled compounds
in human subjects and animals, combined with compartmen-
tal modelling
(9–11,20–23). Biochemical markers of vitamin D,
Ca and P metabolism and liver and kidney function were
measured in fasting blood and urine samples collected at
baseline (day 0) and on day 15 after the dose. After voiding
of the ﬁrst morning urine, a 2h fasting urine was collected
from approximately 07.00 hours. The subject was asked to
drink 500ml of water at both 30min and 1·5h in the 2h
period (total water intake, 1000ml). Blood was collected 1h
into the urine collection. On day 1 (within 5d of the baseline
sample), the 25(OH)D2 dose was administered in the morning
at approximately 07.30 hours after an overnight fast. The dose
was removed from the freezer, protected from light and
brought to room temperature on a rotary mixer. Each dose
was pipetted onto a small piece of local white bread. The vol-
unteer ate the bread under supervision followed by a standar-
dised meal of bread with mayonnaise (Armanti brand; NGM
International Ltd, Rotterdam, The Netherlands). Water was
provided ad libitum. Subjects were supervised for 5h follow-
ing the dose and were allowed to sit or move about freely
within the ﬁeld station but were asked to refrain from lying
down or exercise during this period to minimise the inﬂuence
of gastric emptying. After 5h, a meal was provided. Blood
samples in the ﬁrst group were collected from an in-dwelling
cannula inserted into a forearm or by venepuncture directly
before and every 2h after administration of the dose for a
total of 12h. After the blood sample at 12h, a meal was pro-
vided and the volunteer was free to leave. Further fasting
blood samples were collected after 24 and 48h and on day
15 following the dose. For individuals in the second group,
fasting blood samples were collected by venepuncture at
approximately 08.00 hours on day 3 (corresponding to the
48h sample in the absorption group), 4, 5, 6, 9, 12, 18 and 21.
Sample collections and laboratory analyses
Blood samples were collected into tubes containing EDTA or
lithium heparin (S-Monovettes; Sarstedt Limited, Leicester,
UK) and immediately placed on ice. Lithium-heparin blood
samples for the measurement of ionised Ca (iCa) were
measured within two minutes of collection using an ABL77
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nblood gas analyser (Radiometer, Brønshøj, Denmark) and the
remaining samples were placed on ice. Corrected iCa values at
pH 7·4 were used. Plasma was separated within 30min of col-
lection in a refrigerated centrifuge at 1800g for 20min, and
stored at 2708C. Collected urine was mixed thoroughly, and
non-acidiﬁed and acidiﬁed (HCl, 10ml/l, laboratory reagent
grade, SG 1.18, Fisher Scientiﬁc, Loughborough, UK) aliquots
were taken and stored at 2208C. After completion of the
study, samples were packed and shipped on dry ice to MRC
Human Nutrition Research, Cambridge for analysis. All
assays were performed in duplicate with the exception of
parathyroid hormone (PTH). Total Ca, P, Cr, total alkaline
phosphatase, albumin and cystatin C were measured in hepar-
inised plasma using colorimetric methods on the Kone Lab 20i
clinical chemistry analyser platform (Kone, Espoo, Finland).
On the same platform, urinary Ca (uCa), phosphate (uP)
and creatinine (uCr) were measured in acidiﬁed urine.
Within- and between-assay CV for all Kone assays were ,2
and ,4%, respectively. Concentrations of uCa and uP are
expressed as a ratio relative to uCr to adjust for urine
volume. EDTA plasma was used for the analysis of PTH by
immunoassay (Immulite; Siemens Healthcare Diagnostics Lim-
ited, Camberley, UK). Between-assay CV was 4·7%. Total
plasma 1,25(OH)2D was measured with a RIA (IDS Limited,
Tyne and Wear, UK). Within- and between-assay CV were
7·5 and 9·0%. Cross-reactivity of the assay was 100 and 91%
for 1,25(OH)2D3 and 1,25(OH)2D2, respectively. Assay per-
formance was monitored using kit and in-house controls
and under strict standardisation according to ISO 9001:2000.
Quality assurance of 25(OH)D, 1,25(OH)D and PTH assays
was performed as part of the Vitamin D External Quality
Assessment Scheme (www.deqas.org) and the National Exter-
nal Quality Assessment Scheme (www.ukneqas.org.uk), and
was within the accepted limits.
MS
25(OH)D2 and 25(OH)D3 were measured using ultra-
performance LC-tandem MS
(18). In brief, plasma proteins
were precipitated with acetonitrile, dried and then reconsti-
tuted in deionised water, subjected to solid-phase extraction
and, again, dried. The samples were then derivatised with
50ml 4-phenyl-1,2,4-triazoline-3,5-dione (0·5mg/ml) solution
in acetonitrile. Then, 10ml were injected into the ultra-
performance LC system (Waters, Elstree, Herts, UK) consisting
of Acquity UPLC BEH C18 1·7mm, 2·1 £ 50mm columns
(Waters) and a mobile-phase gradient of 0·1% formic acid
and 5mM-methylamine in water and 0·1% formic acid in
methanol. For MS/MS analysis, a QTRAP triple quadrupole
linear ion trap system (MDS Analytical Technologies, Concord,
Canada) was operated in the electrospray ionisation positive
ion multiple reaction monitoring mode. d6-25(OH)D2 and
d6-25(OH)D3 were used as stable isotope-labelled internal
standards (Chemaphor Limited, Ottawa, Canada). Ion tran-
sitions monitored were 619m/z ! 298m/z for 25(OH)D2,
625m/z ! 298m/z for d6-25(OH)D2, 607 m/z ! 298 m/z for
25(OH)D3 and 613 m/z ! 298 m/z for d6-25(OH)D3. Intra-
and inter-day CV were 1·6 and 3·7% for 25(OH)D2 and 3·8
and 5·8% for 25(OH)D3
(18). The CVof duplicate measurements
of the samples in the present study was less than 3% for both
25(OH)D2 and 25(OH)D3.
Data handling
Data modelling and statistics were performed in Microsoft
Excel 2003 (Microsoft Corporation, Seattle, WA, USA) and
Data Desk 6.0 (Data Description, Ithaca, NY, USA). Within-
and between-group differences were analysed with paired
and unpaired t tests, respectively.
In order to describe the absorption and initial distribution of
25(OH)D2, we used the following equation:
dqA
dt
¼
F 2 kAqA t # T
2kA t . T
(
; ð1Þ
where qA is the amount of 25(OH)D2 in a single compartment,
F is the input constant, kA is the fractional rate constant of loss
and T is the duration of the input. This model assumes a single
compartment, a constant input of the 25(OH)D2 dose and ﬁrst-
order disappearance. Initial estimates of the model parameters
were then subsequently adjusted with the Solver function in
Excel to minimise the differences between the modelled (pre-
dicted) and observed data. The absorption parameter T is
equivalent to Tmax (the time taken to reach the maximum
plasma concentration, Cmax). Cmax was calculated from the
absorption parameters F, T and kA using the following
equation:
Cmax ¼
F
kA
£ 1 2 e2kT: ð2Þ
Plasma 25(OH)D2 half-life was calculated from the
following equation:
T
1
2
¼
lnð2Þ
kB
: ð3Þ
From visual inspection of the logarithmically transformed
curves, kB (the slope of terminal disappearance)
(24) was ident-
iﬁed to commence from day 6. kB was then derived from data
obtained between days 6 and 21 and was calculated from
the slope of the line of best-ﬁt of the natural logarithm of
25(OH)D2 concentration against time.
Results
Biochemical markers of vitamin D, calcium and phosphate
metabolism
There were no signiﬁcant differences in any of the subjects or
biochemical parameters between the groups at day 0 or 15,
thus the groups were combined for further analysis of bio-
chemical parameters (Table 1). There were no signiﬁcant
changes in plasma iCa, total Ca, P, PTH and 1,25(OH)2D, or
uCa/uCr and uP/uCr between days 0 and 15 (Table 1). A sig-
niﬁcant decrease was observed in total alkaline phosphatase
(P¼0·012) and a signiﬁcant increase in plasma creatinine
(P¼0·047), but not in cystatin C. However, all values for
kidney and liver function were within the normal clinical
K. S. Jones et al. 1130
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biochemical abnormalities were detected and values were
comparable with other data obtained from this age group
and population
(25). Total 25(OH)D was calculated as the
sum of 25(OH)D2 and 25(OH)D3 plasma concentrations.
There was no signiﬁcant difference in total 25(OH)D or
25(OH)D3. The plasma concentration of 25(OH)D2 increased
signiﬁcantly from 1·1 (SD 0·5) at day 0 to 3·1 (SD 0·2)nmol/l
at day 15 (P.0·0001). During the study, there were no reports
of side effects or sickness.
Absorption, distribution and terminal slope of
25-hydroxyvitamin D2
Low but detectable concentrations of 25(OH)D2 were
observed in all subjects and time points; therefore, all sub-
sequent concentrations used for data modelling and half-life
calculations were corrected for baseline 25(OH)D2. Cmax was
9·6 (SD 0·9)nmol/l and was observed at Tmax, 4·4 (SD 1·8)h
(Figs. 1 and 2). The input constant, F, was 2·6nmol/h. The
initial disappearance rate constant (kA) calculated from the
peak of the absorption curve and using the remaining data
points after Tmax until 48h was 0·36 (SD 0·14). Individual
plasma response curves are plotted in Fig. 2 and highlight
the consistent pattern between individuals. For the second
group sampled between days 3 and 21, values are plotted
on a semi-logarithmic scale. From a visual inspection of
25(OH)D2 concentration against time (Figs. 3 and 4), a
linear relationship was observed from day 6 onwards. The
plasma concentration of 25(OH)D2 (baseline subtracted)
decreased from 3·4nmol/l at day 6 to 1·5nmol/l at day 21.
This terminal disappearance phase (kB) between days 6 and
21 had a slope of 0·05 (SD 0·01). The mean half-life as
calculated from individual slopes was 13·4 (SD 2·7)d. Individ-
ual plasma curves (Fig. 4) highlight again the consistent
pattern between individuals and clearly show that by day 6,
25(OH)D2 disappearance was in the terminal phase in all
subjects.
We explored relationships between Cmax, Tmax and half-life
and selected physiological and biochemical parameters. A sig-
niﬁcant positive correlation was found between Cmax and BMI
(r 0·87; P¼0·02) but not with height (r 0·03; P¼0·96) and
weight (r 0·73; P¼0·10). There was no association between
either Tmax or Cmax and baseline 25(OH)D3 plasma con-
centration. There were no signiﬁcant relationships between
half-life and measures of plasma iCa, total Ca, P, PTH,
1,25(OH)D or 25(OH)D3 at day 15.
Discussion
The half-life of 25(OH)D may provide a useful biomarker to
investigate vitamin D requirements. In the present pilot
study, we characterised the absorption, distribution and
terminal disappearance of 25(OH)D2 as a tracer to investigate
vitamin D metabolism and to obtain baseline data for future
studies. The protocol was feasible under ﬁeld conditions
and was well accepted by the subjects. The absorption par-
ameters obtained in the present study indicated that the
dose was consistently well absorbed. The data showed that
the terminal slope commenced at day 6. The increase in the
plasma concentration of 25(OH)D2 at the commencement of
the terminal slope was 3·4nmol/l, approximately 6% of the
total plasma concentration of 25(OH)D. This, together
with the lack of evidence of signiﬁcant changes in Ca, P or
vitamin D metabolism, demonstrates that there was no pertur-
bation of the steady state.
The absorption and half-life of 25(OH)D3 in healthy individ-
uals have been measured in a number of studies (summarised
in Tables 2 and 3). Absorption studies frequently used very
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Fig. 1. Plasma appearance and disappearance over 48h after an oral dose
of 25-hydroxyvitamin D2 (25(OH)D2) in the absorption group. Values are
means (n 6), with standard deviations represented by vertical bars, and the
mean modelled plasma concentration represented by a dashed line (n 6).
Table 1. Baseline and day 15 post-dose plasma and urinary concen-
trations of calcium (uCa) and phosphate (uP), and calciotropic hor-
mones†
(Mean values and standard deviations, n 12)
Baseline (day 0)‡ Post-dose (day 15)‡
Mean SD Mean SD
25(OH)D2 (nmol/l) 1·1 0·5 3·1* 0·2
25(OH)D3 (nmol/l) 54·3 10·4 52·9 9·8
1,25(OH)2D (pmol/l) 250·3 57·6 258·6 55·2
PTH (pg/ml)
Geometric mean 71·8 83·2
CI 48·0, 107·6 54·6, 127·0
iCa§ (mmol/l) 1·06 0·05 1·07 0·03
Ca (mmol/l) 2·29 0·09 2·27 0·08
P (mmol/l) 1·34 0·25 1·34 0·20
Albumin (g/l) 38·80 2·45 38·23 2·60
Creatinine (mmol/l) 82·47 7·54 83·55** 5·73
Cystatin C (mg/l) 0·92 0·14 0·89 0·12
TALP (U/l) 262·8 76·6 240·1*** 64·0
uCa/uCr (mmol/l) 0·08 0·08 0·07 0·06
uP/uCr (mmol/l) 1·11 0·40 1·44 0·55
25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; PTH, para-
thyroid hormone; iCa, ionised calcium; TALP, total alkaline phosphatase; uCr,
urinary creatinine.
† There were no signiﬁcant differences between the absorption group (n 6) and the
half-life group (n 6) in any of the subjects or biochemical characteristics.
‡ Mean values were signiﬁcantly different from baseline values (day 0):
*P#0·0001; **P¼0·047; ***P,0·05 (paired t test).
§ Corrected value at pH 7·4.
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vitamin D metabolism (Table 2). Studies reporting 25(OH)D3
half-lives using unlabelled, radiolabelled and stable isotope-
labelled compounds after oral or intravenous administration
have reported widely different values (Table 3). Nevertheless,
within-study comparisons demonstrated differences in
25(OH)D3 half-life between controls and anephrics
(9) and
between individuals on either a high- or normal-ﬁbre
diet
(11). The wide variation between methods may have
been caused by methodological differences and limitations
in the experimental design or quantiﬁcation techniques,
such as an improperly deﬁned terminal slope or measurement
of total radioactivity.
There are advantages to using oral 25(OH)D3 rather than
vitamin D3 to measure 25(OH)D3 half-life that are based on
a number of factors which relate to differences in absorption,
tissue distribution and hepatic metabolism
(21,26–29). In view of
the similarities in the absorption and distribution of vitamin D2
and vitamin D3
(30–32), these advantages may also apply to
25(OH)D2. Absorption of 25(OH)D3 is greater, faster and
more consistent than that of vitamin D3
(33). Net absorption of
vitamin D3 in healthy human subjects has been reported to
be between 55 and 99% of the dose
(21,34), whereas
25(OH)D3 absorption ranged from 88 to 100% in healthy sub-
jects. This may be related to the difference in absorption
mechanism, i.e. for vitamin D3, this is primarily into the enter-
ocytes and the lymph system whereas the primary route for
25(OH)D3 absorption is via the portal vein
(35,36), although
another study has suggested that the absorption mechanism
is the same for vitamin D and 25(OH)D
(37). Differences in
the principal absorption mechanism are also supported by evi-
dence from studies in patients with various gastrointestinal
disorders affecting chylomicron formation, in which absorp-
tion of vitamin D is affected to a greater extent than
25(OH)D
(20,21,26). Vitamin D metabolites in the circulation
are predominantly bound to DBP; however, a proportion of
an oral dose, particularly for the less-polar vitamin D, will
initially be associated with chylomicrons that may further
inﬂuence initial metabolism and sequestration into body
tissues. Therefore, in terms of delivering the maximum and
most consistent plasma response from a minimum tracer
dose, 25(OH)D is more effective than vitamin D.
For the determination of 25(OH)D half-life, the use of a
tracer or labelled 25(OH)D rather than tracer or labelled
precursor (i.e. vitamin D) is also likely to reduce variability
because factors are removed that will inﬂuence the rate of
appearance of 25(OH)D in the circulation. The appearance
of 25(OH)D after a bolus dose of vitamin D is determined
by the rate and extent of hepatic hydroxylation and sequestra-
tion and release of vitamin D from body stores. Little is known
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Fig. 2. Plasma appearance and disappearance over 48h after an oral dose of 25-hydroxyvitamin D2 (25(OH)D2) in six subjects (A–F) in the absorption group.
W, Observed plasma concentration of 25(OH)D2; —, modelled plasma curve.
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Fig. 3. Semi-logarithmic plot of plasma concentration between days 3 and 21
after an oral dose of 25-hydroxyvitamin D2 (25(OH)D2) in the half-life group
(n 6). Values are means, with standard deviations represented by vertical
bars, and the terminal slope (0·05 (SD 0·01)) calculated from day 6 onwards
represented by a dashed line.
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nabout the relationship between the serum concentration of
vitamin D and its tissue distribution. Appreciable amounts of
vitamin D may be taken up by tissues (principally adipose
tissue) and this may be inﬂuenced by the plasma concen-
tration of 25(OH)D and saturation of the 25-hydroxylase
enzyme
(38). The majority of 25(OH)D is found in plasma,
with smaller amounts in fat and fat-free mass
(29,38). The poten-
tial slow release of tracer vitamin D from body stores and the
consequent further and additional hepatic production of
labelled 25(OH)D into the circulation would cause ﬂuctu-
ations in labelled 25(OH)D concentration and may distort
the 25(OH)D half-life. The use of tracer 25(OH)D prevents
the continued production of labelled 25(OH)D from labelled
vitamin D and allows the establishment of faster equilibrium
between body pools. In some earlier studies, increased
variability may have been caused by measurement of total
radioactivity that included the vitamin D3 dose and all down-
stream metabolites (predominantly 25(OH)D3, 1,25(OH)2D3
and 24,25(OH)2D3), and therefore affected the accuracy of
the calculated half-life. However, it was reported that between
4 and 40d after a dose of vitamin D3 or 25(OH)D3, more than
80% of radioactivity is associated with 25(OH)D3.U pt o5 %
remains associated with vitamin D3 and up to 10% with
more polar metabolites
(8,9). Modern LC-MS/MS, as used in
the present study, enhances the measurement speciﬁcity.
In the present study, as expected, the oral dose increased
25(OH)D2 concentrations (Figs. 1 and 2). Cmax was 9·6 (SD
0·9)nmol/l and occurred at Tmax, 4·4 (SD 1·8)h. These data sup-
port the notion of rapid and efﬁcient absorption in the upper
gastrointestinal tract. The results of absorption parameters
Cmax and Tmax from the present study are similar to those pre-
viously observed for 25(OH)D3 (Table 2). This observation is
consistent with comparisons of vitamin D2 and vitamin D3
absorption where no differences have been observed in the
initial plasma response after oral doses
(30–32,39). The small
standard deviations in the absorption parameters demonstrate
Table 2. Absorption of 25-hydroxyvitamin D (25(OH)D) measured with oral doses of unlabelled or radiolabelled 25(OH)D
(Mean values and standard deviations or standard errors)
Dose nT max (h) Cmax (nmol/l)*
The present study 25(OH)D2 33mg( 0 · 5–0 · 7mg/kg) 6 4·4† 9·6‡
Haddad & Rojanasathit
(10) Unlabelled 25(OH)D3 1·5, 5 or 10mg/kg 22 4–8 <90, 200 and 375, respectively
[
3H]25(OH)D3 (1·8 nmol) þ 26mg reference 25(OH)D3 3 6–10 NR
Stamp
(65) Unlabelled 25(OH)D3 10mg/kg body weight 12 4–8 272§
Compston & Creamer
(66) Unlabelled 25(OH)D3 10mg/kg body weight 15 8 258–465
Davies et al.
(21) [
3H]25(OH)D3 26mg5 7 · 2 k 6·7{
Sitrin & Bengoa
(20) [
3H]25(OH)D3 with 100 mg unlabelled 25(OH)D3 4 8 42% dose in total plasma volume
Leichtmann et al.
(22) [
3H]25(OH)D3 with 100 mg unlabelled 25(OH)D3 4 8 37% dose in total plasma volume
Compston et al.
(27) [
3H]25(OH)D3 8N R <48% dose in total plasma volume
NR, not reported.
* To convert nmol/l to mg/l, multiply by 0·400 for 25(OH)D3 and 0·412 for 25(OH)D2.
† SD 1·8h.
‡ SD 0·9nmol/l.
§ SD 33nmol/l.
k SE 0·5h/l.
{ SE 0·9nmol/l.
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Fig. 4. Semi-logarithmic plot of plasma disappearance from days 3 to 21 after an oral dose of 25-hydroxyvitamin D2 (25(OH)D2) in six subjects (H–M) in the
half-life group. W, Observed plasma concentration of 25(OH)D2; —, line of best ﬁt between days 6 and 21.
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nlimited variation in absorption between individuals and in com-
parison with previous 25(OH)D3 absorption studies (Table 2).
Althoughtheanalysiswasrestrictedtosixsubjects,weobserved
a signiﬁcant positive correlation between Cmax and BMI and
a similar but not signiﬁcant correlation between Cmax and
weight. However, a negative correlation with fat-free mass
(and potentially fat mass) may be expected because of the
potentially larger dilution volume and/or tissue absorptive
capacity in subjects with more fat-free mass or fat mass.
Although we did not measure body composition in the present
study, the body habitus of the study subjects is consistent with
that measured previously in this population with relatively
little fat mass
(40).
We identiﬁed the terminal phase to commence from day 6
(Figs. 3 and 4) and the terminal plasma half-life of
25(OH)D2 was determined to be 13·4 (SD 2·7)d (range
9·6–17·3d). This is somewhat less than half-lives reported
earlier in healthy individuals after doses of radiolabelled vita-
min D3 or 25(OH)D3 (Table 3), which ranged from 10 to 40d.
The only study that used a stable isotope-labelled compound
has reported a value of 10·4d
(12). Half-life was not associated
with the underlying plasma concentration of 25(OH)D3 and
may not be surprising given the relatively narrow range of
concentrations (range 38·4–69·0nmol/l). This observation is
consistent with some studies
(41,42) but not with others
(7,43),
and is an area that requires further investigation. The short
half-life in the present study may be due to differences in
half-life between 25(OH)D2 and 25(OH)D3, the study popu-
lation or the experimental approach between the present
and other studies (Table 3). Evidence from studies using
unlabelled compounds suggests that 25(OH)D2 is cleared
more rapidly from plasma than 25(OH)D3
(30,31,39), and this is
thought to be due to their relative binding afﬁnities for
DBP
(13,14,44). Alternatively, correction for 25(OH)D2 concen-
tration at baseline and subsequent inconsistent intake during
the study period may have introduced variability in plasma
concentrations of 25(OH)D2. In the absorption phase, ﬂuctu-
ation in 25(OH)D2 plasma concentration is likely to have
had only a very minor effect because of the higher concen-
tration from the dose and shorter time period. However, ﬂuc-
tuations in vitamin D2 intake may have contributed more
signiﬁcantly to variability in 25(OH)D2 half-life because of
the lower concentrations during the terminal slope. In
addition, the unexpected baseline levels of 25(OH)D2 and
subsequent subtraction may have introduced additional error
in the determination of half-life. This population in
rural Gambia is known to have a low dietary Ca intake
(300–400mg/d)
(25,45), a high ﬁbre intake and elevated
1,25(OH)2D and secondary hyperparathyroidism
(25), and are
consistent with the ﬁndings of the present study. All these
factors are known to increase 25(OH)D turnover
(11,46,47).
Furthermore, longitudinal bone growth and bone mineral
accrual still occurs in Gambian men of this age
(48), thus their
tissue requirement for Ca and vitamin D may be higher than
an older age group
(49–51). Total 25(OH)D was calculated as
the sum of 25(OH)D2 and 25(OH)D3 concentrations
as measured by LC-MS/MS. In the present study, the mean
baseline total 25(OH)D plasma concentration was about
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n55nmol/l. Notwithstanding known assay differences
(52,53), this
value is somewhat lower than previous measurements in
this and other age groups in The Gambia
(25) and Guinea-
Bissau
(54), and may be surprising given the year-round ability
for cutaneous vitamin D production and plentiful sunshine
(19).
The relatively low values could be attributable to a number of
causes as discussed above (i.e. skeletal development and low
Ca intake).
Plasma 25(OH)D3, total 1,25(OH)2D, PTH, Ca, iCa and P
and uCa and uP did not change from baseline, indicating
that the tracer did not perturb Ca, P and vitamin D metab-
olism. This contrasts with another study in which a much
higher dose (1mg) resulted in elevated uCa and hydroxypro-
line but without changes in plasma values of Ca or P
(10).
This indicates alterations of Ca and bone metabolism and
the resultant half-life may therefore not be reﬂective of
habitual vitamin D turnover
(10).
25(OH)D2 can only be used as a tracer in a population with
absent or very low 25(OH)D2 plasma concentration, or after a
period of weeks or months of vitamin D2 depletion, and thus
its use may be not be suitable in all populations, although
recent evidence suggests that circulating plasma levels in
the UK are similar to those observed in the present study
(H. Macdonald, personal communication). This study was per-
formed in a rural Gambian village where vitamin D2 intake was
not expected. This was supported by recent work from Guinea-
Bissau in which 25(OH)D2 measured by LC/MS was detected in
only seven out of 856 subjects
(54). Surprisingly, however, low
but detectable concentrations of 25(OH)D2 (ranging from 0·6
to 2·5nmol/l) were found in all baseline samples from all
subjects. An explanation for this observation may be the non-
listing of vitamin D2 as an additive to products available in
local shops (such as margarine, milk powder or mayonnaise),
the availability of other fortiﬁed food through food aid pro-
grammesor,alternatively,ingestionfromplant-orfungi-derived
vitamin D2 from sun-drying and/or fungal contamination of
food crops. The presence of vitamin D2 has been demonstrated
in sun-dried alfalfa at a concentration of 48ng/g
(55). An alterna-
tive explanation is an interfering compound co-extracted
with the vitamin D metabolites. However, given the speciﬁcity
of the tandem MS method, this seems unlikely since such an
interfering compound would have the same retention times
and the same precursor and product ions.
There are some differences in the metabolism of 25(OH)D2
and 25(OH)D3 that may limit the comparability of the
measured half-lives of the two forms. Afﬁnities of 25(OH)D2
and 25(OH)D3 to DBP are not the same and may affect
plasma half-life
(14,44). It is also possible that differences in
distribution, either independent of or related to the afﬁnity
to DBP, may result in additional differences in clearance.
At a molecular level, there are differences in the afﬁnity
of CYP24A1, being lower for 1,25(OH)2D2 than for
1,25(OH)2D3
(56). However, 25(OH)D2 and 25(OH)D3 are
metabolised at similar rates by CYP27B1
(57,58) and CYP24A1
enzymes
(57), although differences in the hydroxylation pro-
ducts and downstream metabolites of vitamin D2 and vitamin
D3 may exist
(59,60). At the physiological level, however, the
majority of evidence suggests no difference in the suppressive
effect of 25(OH)D2 and 25(OH)D3 on PTH
(31,32,61–64).
In conclusion, unlabelled 25(OH)D2, together with sensitive
MS, provide a cost-effective and readily available alternative to
labelled tracer molecules in populations with expected low or
absent plasma 25(OH)D2 but further studies are required to
directly compare the metabolism and half-life of 25(OH)D2
and 25(OH)D3 to validate the use of 25(OH)D2. The data
from the present study will help reﬁne a ﬁeld protocol to
measure 25(OH)D2 half-life and, given the similarity in
absorption between 25(OH)D2 and 25(OH)D3, will underpin
the development of a protocol to determine 25(OH)D3 half-
life suitable for use in adults and children. In populations
with higher Ca intake and therefore lower vitamin D usage,
a longer half-life might be expected. Additional studies are
required to optimise the duration of sample collection to esti-
mate half-life in different populations. 25(OH)D half-life may
be useful as a biomarker of vitamin D metabolism to investi-
gate environmental or physiological factors that may affect
vitamin D usage and to better assess vitamin D requirements.
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